Lindsay M Morton


Affiliation: National Institutes of Health
Country: USA


  1. Black A, Gibson T, Shiels M, Park Y, Robien K, Albanes D, et al. Pooling prospective studies to investigate the etiology of second cancers. Cancer Epidemiol Biomarkers Prev. 2014;23:1598-608 pubmed publisher
    ..Increased understanding of nontreatment risk factors for second cancers will provide valuable prevention and surveillance information. ..
  2. Morton L, Wang S, Cozen W, Linet M, Chatterjee N, Davis S, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood. 2008;112:5150-60 pubmed publisher
  3. Morton L, Wang S, Richesson D, Schatzkin A, Hollenbeck A, Lacey J. Reproductive factors, exogenous hormone use and risk of lymphoid neoplasms among women in the National Institutes of Health-AARP Diet and Health Study Cohort. Int J Cancer. 2009;124:2737-43 pubmed publisher
    ..These data do not support an important role for reproductive factors or exogenous hormones in modulating lymphomagenesis. ..
  4. Morton L, Saber W, Baker K, Barrett A, Bhatia S, Engels E, et al. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report. Biol Blood Marrow Transplant. 2017;23:367-378 pubmed publisher
  5. request reprint
    Morton L, Cahill J, Hartge P. Reporting participation in epidemiologic studies: a survey of practice. Am J Epidemiol. 2006;163:197-203 pubmed
    ..The authors conclude that epidemiologists need to address declining participation and to report participation consistently, including for biologic specimen collection. ..
  6. Zamoiski R, Yanik E, Gibson T, Cahoon E, Madeleine M, Lynch C, et al. Risk of Second Malignancies in Solid Organ Transplant Recipients Who Develop Keratinocyte Cancers. Cancer Res. 2017;77:4196-4203 pubmed publisher
    ..Cutaneous SCC occurrence after transplantation could serve as a marker for elevated malignancy risk. Cancer Res; 77(15); 4196-203. ©2017 AACR. ..
  7. Morton L, Schenk M, Hein D, Davis S, Zahm S, Cozen W, et al. Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma. Pharmacogenet Genomics. 2006;16:537-45 pubmed
    ..15-5.20, P = 0.02). Our data provide evidence that NAT1 and NAT2 genotypes are associated with NHL risk and support a contributory role for carcinogenic aromatic and/or heterocyclic amines in the multi-factorial etiology of NHL. ..
  8. request reprint
    Morton L, Wang S, Bergen A, Chatterjee N, Kvale P, Welch R, et al. DRD2 genetic variation in relation to smoking and obesity in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Pharmacogenet Genomics. 2006;16:901-10 pubmed
    ..Our results further support evaluation of DRD2 antagonists for obesity therapies. ..
  9. Morton L, Bernstein L, Wang S, Hein D, Rothman N, Colt J, et al. Hair dye use, genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma. Carcinogenesis. 2007;28:1759-64 pubmed
    ..We present the first evidence suggesting that this risk may differ by genetic variation in NAT1 and NAT2. ..

More Information


  1. Morton L, Purdue M, Zheng T, Wang S, Armstrong B, Zhang Y, et al. Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development. Cancer Epidemiol Biomarkers Prev. 2009;18:1259-70 pubmed publisher
    ..Replication of our findings and further study to identify functional SNPs are warranted. ..
  2. Morton L, Curtis R, Linet M, Bluhm E, Tucker M, Caporaso N, et al. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol. 2010;28:4935-44 pubmed publisher